Balyasny Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Balyasny Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-383,948	Closed	-$7.24M	–	1636
2019 Q3	$7.24M	Buy	+383,948	New	+$4.39M	0.05%	480
2019 Q2	–	Sell	-106,682	Closed	-$1.46M	–	1843
2019 Q1	$1.46M	Buy	106,682 +81,381	+322%	+$1.05M	0.01%	911
2018 Q4	$259K	Buy	+25,301	New	+$324K	﹤0.01%	1257
2018 Q2	–	Sell	-54,349	Closed	-$690K	–	2335
2018 Q1	$690K	Sell	54,349 -552,946	-91%	-$8M	﹤0.01%	1350
2017 Q4	$6.95M	Buy	607,295 +585,421	+2,676%	+$6.53M	0.02%	746
2017 Q3	$268K	Buy	+21,874	New	+$228K	﹤0.01%	1585

Balyasny Asset Management's ALDR Position: Q4 2019 in Review

Balyasny Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 383,948 shares — an estimated $7.24M sold.

Balyasny Asset Management first reported a position in ALDR in Q3 2017 and held it in 6 quarters. The position peaked at $7.24M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Balyasny Asset Management reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Balyasny Asset Management sold 383,948 Alder Biopharmaceuticals shares in Q4 2019, an estimated $7.24M.
Balyasny Asset Management first reported a position in Alder Biopharmaceuticals in Q3 2017 and held it in 6 quarters.
Balyasny Asset Management's Alder Biopharmaceuticals position peaked at $7.24M in Q3 2019.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Balyasny Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.